PARP1 and hepatocellular carcinoma: Chang et al. uncovered a negative correlation between the expression of YAP1, a promoter of stemness-related genes SOX2 and OCT4, and the sensitivity of liver cancer cells to sorafenib.890 Viral infection-associated hepatocellular carcinoma cells (vHCC) exhibit resistance to sorafenib.891 The activated Interferon-Gamma Receptor (IFNGR)/JAK2/STAT1/Poly(ADP-Ribose) Polymerase 1 (PARP1) pathway in vHCC maintains stemness, leading to resistance to sorafenib.